Polymorphism analysis of estrogen receptor β Gene RsaI and AluI in girls with idiopathic central precocious puberty: investigating the relationship and implications for early risk prediction - Scorecard - MDSpire

Polymorphism analysis of estrogen receptor β Gene RsaI and AluI in girls with idiopathic central precocious puberty: investigating the relationship and implications for early risk prediction

  • By

  • Peipei Liu

  • Guoqing Dong

  • Mingzhu Li

  • Miao Huang

  • Xiyan Lu

  • Jianxu Li

  • June 17, 2026

  • 0 min

Share

Clinical Scorecard: Genetic Variants of Estrogen Receptor β Gene RsaI and AluI in Girls with Idiopathic Central Precocious Puberty: Exploring Their Association and Potential for Early Risk Assessment

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationGirls aged 4 to 9.2 years
Care Setting

Key Highlights

  • Rraa_haplotype

Guideline-Based Recommendations

Diagnosis

    Management

    • I
    • n
    • c
    • l
    • u
    • d
    • e
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • t
    • r
    • e
    • a
    • t
    • m
    • e
    • n
    • t
    • o
    • p
    • t
    • i
    • o
    • n
    • s
    • b
    • a
    • s
    • e
    • d
    • o
    • n
    • g
    • e
    • n
    • e
    • t
    • i
    • c
    • f
    • i
    • n
    • d
    • i
    • n
    • g
    • s
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Expand on how genotyping assists in early risk assessment.

        Clinical Best Practices

        • follow_up

        Related Resources & Content

        Original Source(s)

        Polymorphism analysis of estrogen receptor β Gene RsaI and AluI in girls with idiopathic central precocious puberty: investigating the relationship and implications for early risk prediction

        • by Peipei Liu, Guoqing Dong, Mingzhu Li, Miao Huang, Xiyan Lu, Jianxu Li

        • June 17, 2026

        Related Content

        Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer

        FDA Monthly Preview: Key June Decisions to Watch

        Several FDA decisions across multiple specialties are expected this month.

        SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

        A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.